AstraZeneca PLC (AZN)vsInnovAge Holding Corp (INNV)
AZN
AstraZeneca PLC
$155.62
+3.78%
HEALTHCARE · Cap: $263.09B
INNV
InnovAge Holding Corp
$11.09
+2.21%
HEALTHCARE · Cap: $1.57B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6365% more annual revenue ($61.37B vs $949.17M). AZN leads profitability with a 17.0% profit margin vs -1.2%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
INNV
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$155.62
$41.31 discount
Margin of Safety
-24.5%
Fair Value
$6.57
Current Price
$11.09
$4.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
15.5% revenue growth
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -9.7% — below average capital efficiency
Earnings declined 87.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : INNV
The strongest argument for INNV centers on Revenue Growth. Revenue growth of 15.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : INNV
The primary concerns for INNV are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while INNV is a growth play — different risk/reward profiles.
INNV carries more volatility with a beta of 0.35 — expect wider price swings.
INNV is growing revenue faster at 15.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 24/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
InnovAge Holding Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
InnovAge Holding Corp. The company is headquartered in Denver, Colorado.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?